9 To 11 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.6)
  • Patent number: 11779628
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 10, 2023
    Assignee: XIGEN INFLAMMATION LTD.
    Inventors: Jean-Marc Combette, Catherine Deloche
  • Patent number: 11759444
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 19, 2023
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrej Jancarik, Robert Leone, Judson Englert
  • Patent number: 11628209
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 18, 2023
    Assignees: Tron GGMBH, BioNTech SE
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • Patent number: 11253604
    Abstract: The present invention relates to a compound having a structure in which methotrexate and a peptide are connected via a covalent bond, and an anticancer or anti-inflammatory pharmaceutical composition comprising same. The compound having a structure in which methotrexate and a peptide are connected via a covalent bond of the present invention has excellent biological activity such as anticancer or anti-inflammatory action and has markedly reduced toxicity with respect to cells, and thus, may be usefully used in various fields such as medicine and medical supplies.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 22, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim, Seon Soo Kim
  • Patent number: 10662222
    Abstract: A peptide comprising a sequence for opening a tight junction of an epithelial surface and optionally a cell penetrating sequence; and related compositions, optionally comprising further pharmaceutical agents; and related methods.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: May 26, 2020
    Assignee: The University of Bath
    Inventor: Randall Jay Mrsny
  • Patent number: 10188712
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 29, 2019
    Assignees: BIONTECH AG, TRON—Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • Patent number: 10072018
    Abstract: The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: September 11, 2018
    Assignee: BIOPHARMA WORKS
    Inventors: Robert Volkmann, Anthony Marfat, Peter Cornelius, Panayiotis Zagouras, Fredrick Raymond Nelson, Anton Franz Joseph Fliri
  • Patent number: 9688722
    Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: June 27, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Patrick A. McKee, Kenneth W. Jackson, Victoria J. Christiansen
  • Patent number: 9187530
    Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 17, 2015
    Assignee: 13THERAPEUTICS, INC.
    Inventors: Sharon L. McCoy, Steven H. Hefeneider
  • Patent number: 9150617
    Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: October 6, 2015
    Assignee: 13THERAPEUTICS, INC.
    Inventors: Sharon L. McCoy, Steven H. Hefeneider
  • Patent number: 9150616
    Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: October 6, 2015
    Assignee: 13THERAPEUTICS, INC.
    Inventors: Sharon L. McCoy, Steven H. Hefeneider
  • Patent number: 9066906
    Abstract: A method of purifying lunasin or a lunasin-containing complex produced in a plant includes providing a plant material from the plant, and isolating the lunasin-containing complex from the plant material, and/or releasing lunasin from the lunasin-containing complex. A composition for treating a cancer or an inflammation-related disease in a subject includes a lunasin-containing complex. A composition for treating a cancer or an inflammation-related disease in a subject includes a lunasin polypeptide and/or a lunasin-containing complex; and curcumin, wherein the combination of the a lunasin polypeptide or lunasin-containing complex and the curcumin has a synergistic effect. A method for treating a cancer or an inflammation-related disease includes administering a composition including a lunasin-containing complex, or a lunasin polypeptide and/or a lunasin-containing complex, and curcumin.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: June 30, 2015
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Keith Davis, Brian Barnett, Jian Cai, Elizabeth McConnell
  • Publication number: 20150148303
    Abstract: The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 28, 2015
    Applicant: NYMOX CORPORATION
    Inventors: Paul AVERBACK, Jack Gemmell
  • Patent number: 9040481
    Abstract: Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: May 26, 2015
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Eva Tomas-Falco
  • Publication number: 20150140060
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventor: Gautam GHATNEKAR
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150133393
    Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 14, 2015
    Inventors: Jean-Marc Combette, Catherine Deloche
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Publication number: 20150126460
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 7, 2015
    Applicant: NoNO Inc.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Publication number: 20150126457
    Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 7, 2015
    Inventors: Dennis J. Goebel, John Marshall
  • Publication number: 20150125478
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 7, 2015
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
  • Publication number: 20150118315
    Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.
    Type: Application
    Filed: June 13, 2012
    Publication date: April 30, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Patent number: 9011867
    Abstract: The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: April 21, 2015
    Assignee: Ruprecht-Karls-Universitat Heidelberg
    Inventors: Michael Hundemer, Olaf Christensen
  • Patent number: 9012403
    Abstract: The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: April 21, 2015
    Assignee: XiberScience GmbH
    Inventors: Peter Petzelbauer, Sonja Reingruber
  • Publication number: 20150105327
    Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Woojin An, Nouri Neamati, Kyunghwan Kim
  • Publication number: 20150104485
    Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.
    Type: Application
    Filed: April 16, 2013
    Publication date: April 16, 2015
    Applicant: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Publication number: 20150105334
    Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.
    Type: Application
    Filed: September 22, 2014
    Publication date: April 16, 2015
    Inventor: Angel PORGADOR
  • Patent number: 9006183
    Abstract: The use of lipopeptides as inducers of NF-?B for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: April 14, 2015
    Assignees: Cleveland Clinic Foundation, Cleveland BioLabs, Inc.
    Inventors: Alexander Shakhov, Andrei Gudkov
  • Patent number: 8999939
    Abstract: A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to ?0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), wherein the amino group may be present in a free or protonated manner, and the carboxy groups may be present in a free or deprotonated manner.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: April 7, 2015
    Assignee: Henkel AG & Co. KGaA
    Inventors: Erik Schulze Zur Wiesche, Petra Westphal, Elisabeth Poppe
  • Patent number: 8999925
    Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 7, 2015
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Jennifer S. Spence, Robert F. Garry
  • Publication number: 20150093463
    Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 2, 2015
    Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
  • Publication number: 20150086557
    Abstract: Provided is a novel ligand for integrin ?9?1 consisting of a peptide having the following amino acid sequence: (A) EDDMMEVPY (SEQ ID NO: 1) or (B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO: 1 except for having deletion, substitution or addition of 1 to 3 amino acids. The novel ligand for integrin ?9?1 has a higher binding affinity than those of tenascin-C and osteodontin, which are known ligands for integrin ?9?1.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Inventors: Kiyotoshi Sekiguchi, Ryoko Sato, Sachiko Ezoe
  • Publication number: 20150080321
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Chiang Jia LI, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Norio Nishihara
  • Publication number: 20150080288
    Abstract: Nitration shielding peptides that reduce or prevent nitration of a protein of interest are disclosed. The peptide can serve as molecular sink for nitrating agents, block access of the nitrating agents to the target tyrosine on the protein of interest, serve as substrate for the nitrating agent (i.e., provide an alternative nitratable tyrosine residue), provide a nitrating agent neutralizing moiety such as antioxidant, or a combination thereof. The nitration shielding peptide can be a fusion protein that includes one or more additional domains such a protein transduction domain, a targeting signal, a purification tag, or any combination thereof. Exemplary nitration shielding peptides for reducing nitration of RhoA and PKG-1?, and methods of use thereof for treating pathologies, disease, and disorders associated with nitration of RhoA and PKG-1?, respectively are also provided.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 19, 2015
    Inventors: Stephen M. Black, Ruslan Robertovich Rafitov
  • Publication number: 20150080322
    Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tomomichi Futo, Kazuhiro Saito, Tetsuo Hoshino, Masuhisa Hori
  • Publication number: 20150079154
    Abstract: The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.
    Type: Application
    Filed: July 9, 2012
    Publication date: March 19, 2015
    Applicant: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Lars Zender, Ramona Rudalska, Daniel Dauch
  • Publication number: 20150071856
    Abstract: The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled-1 and/or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Inventors: Wessel Matthijs Blankesteijn, Hilde Laeremans, Tilman Mathias Hackeng
  • Patent number: 8975229
    Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: March 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda
  • Publication number: 20150065424
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Applicant: VECTUS BIOSYSTEMS LIMITED
    Inventor: Karen Annette Duggan
  • Publication number: 20150065436
    Abstract: The present invention relates to peptidomimetics that mimic helix ?B of the C-terminal transactivation domain of HIF-1?. Methods of using the peptidomimetics to, e.g., inhibit the HIF-1?-p300/CBP interaction, are also disclosed.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA, NEW YORK UNIVERSITY
    Inventors: Paramjit S. ARORA, Brooke Bullock LAO, Laura K. HENCHEY, Nathaniel J. TRAASETH, Paul THOMSON, Swati KUSHAL, Bogdan Z. OLENYUK
  • Publication number: 20150057217
    Abstract: The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below wherein A1, v, A2, w, A3, x, y, A4, z, R1, R2 and R3 are as defined in the application; or a salt thereof. The invention further relates to use of the peptides as antibacterial agents, or antitumor agents, including the medical use of the peptide in treating infection and/or cancer, as well as their use as preservatives and antibacterial agents in other products, including personal care products such as skin topical treatments, cleansers, mouth washes, toothpastes, shampoo, body lotions and creams etc.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 26, 2015
    Inventors: Jian R. LU, Xiubo ZHAO, Fang PAN, Mohammed YASEEN
  • Patent number: 8962571
    Abstract: A method for repairing DNA damage in human keratinocytes by applying to the keratinocytes a composition comprising at least one CLOCK or PER1 gene activator and at least one DNA repair enzyme.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 24, 2015
    Assignee: ELC Management
    Inventors: Daniel H. Maes, Nadine A. Pernodet, Lenny Slutsky, Donald F. Collins, Kerri Goldgraben, Edward Pelle, James Timothy McCarthy
  • Patent number: 8962565
    Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2, cosmetic or pharmaceutical compositions comprising at least one peptide compound of general formula (I) in a physiologically acceptable medium, and methods for cosmetic treatment of skin are disclosed. The peptide compounds of general formula (I) were demonstrated to be agents making it possible to influence the pigmentation of the skin and skin appendages, by ensuring optimal transfer of the melanosomes to the keratinocytes, so as to make the skin tone uniform owing to an effect on the SCF/c-Kit signaling pathway. The compounds, compositions, and methods treat or attenuate age-related pigmentation defects and the effects of photoaging on the skin.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: February 24, 2015
    Assignee: ISP Investments Inc.
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Publication number: 20150051159
    Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
  • Publication number: 20150050211
    Abstract: Provided herein are methods to generate and screen peptides that exhibit drug like stabilities in vitro and in vivo. By selecting for enzyme resistance, Applicants are able to derive peptides that are not only stable to a broad spectrum of proteases, but also stable to other drug processing enzymes such as cytochrome P450s. This approach provides a general method to the rapid development of highly stable peptides for therapeutic development and diagnosis. The peptides are further modified for oral bioavailability.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 19, 2015
    Applicant: University of Souththern California
    Inventors: Stephen V. Fiacco, Terry T. Takahashi, Richard W. Roberts
  • Patent number: 8957030
    Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 17, 2015
    Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de Montreal
    Inventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao